Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy

Journal of Nuclear Medicine

Volumn 46, Issue 2, 2005, Pages 253-260

  Eschmann, Susanne Martina ^a   Paulsen, Frank ^a   Reimold, Matthias ^a   Dittmann, Helmut ^a   Welz, Stefan ^a   Reischl, Gerald ^a   Machulla, Hans Juergen ^a   Bares, Roland ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

18F fluoromisonidazole PET; Hypoxia imaging; Prognosis

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; TRACER; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE RECONSTRUCTION; IMAGING; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; RADIOCHEMISTRY; RELAPSE; STATISTICAL ANALYSIS; TUMOR RECURRENCE; CELL HYPOXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GERMANY; HEAD AND NECK TUMOR; INCIDENCE; LUNG TUMOR; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME; VALIDATION STUDY;

CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; FLUORINE RADIOISOTOPES; GERMANY; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MISONIDAZOLE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 15844368087     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941-943.
2. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289.
3. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26:45-50.
4. Olive PL, Vikse CM, Durand RE. Hypoxic fractions measured in murine tumors and normal tissues using the comet assay. Int J Radiat Oncol Biol Phys. 1994; 29:487-491.
5. Olive PL, Durand RE, Le Riche J, Olivotto IA, Jackson SM. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res. 1993;53:733-746.
6. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s. c. tumors. Cancer Res. 1996;56:405-411.
7. Mathias CJ, Welch MJ, Kilbourn MR, et al. Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. Life Sci. 1987;41:199-206.
8. Koh WJ, Rasey JS, Evans ML, et al. Imaging of tumor hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;199-212.
9. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292-304.
10. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-991.
11. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122: 301-308.
12. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human non small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
13. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18]fluoromisonidazole: a pre-therapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
14. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med. 2003;30:695-704.
15. Chapman JD. Hypoxic sensitizers: implications for radiation therapy. N Engl J Med. 1979;01:1429-1432.
16. Piert M, Machulla HJ, Becker G, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med Mol Imaging. 1999;26:95-109.
17. 18F]fluoromisomdazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol. 2000;27:693-700.
18. Machulla HJ. Imaging of hypoxia-tracer developments. Boston, MA: Kluwer Academic Publishers; 1999.
19. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
20. 18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317-326.
21. 99mTc]HL-91: correlation with microelectrode measurements. J Nucl Med. 2001; 42:337-344.
22. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
23. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995; 194:795-800.
24. 99mTc-HL91, in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med. 2000;41:1102-1107.
25. Ling CC, Humm J, Larson H, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560.
26. Alber M, Paulsen F, Eschmann SM, Machulla HJ. Biologically conformal boost dose optimisation. Phys Med Biol. 2003;48:N31-N35.
27. 18F] fluoromisonidazole by nucleophilic substitution on THP-protected precursor: yield dependence on reaction parameters. J Radioanal Nucl Chem. 1999;240:925-927.
28. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys. 1995; 22:1127-1139.
29. Reinartz P, Gagel B, Zimny M, et al. Tumor hypoxia as prognostic factor: evaluation by [F-18]fluoromisonidazole PET, polarography and FDG-PET. Nucl Med. 2004;43:A28-A29.
30. Meert AP, Maesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87:694-701.